Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance pemetrexed versus placebo after pemetrexed + cisplatin induction in advanced non-squamous non-small cell lung cancer
2008-002155-24Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Maintenance pemetrexed + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Objective progression-free survival time. Started Jul 2008; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-002155-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002155-24.